These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37889067)

  • 1. Molecular Characteristics and Therapeutic Vulnerabilities of Claudin-low Breast Cancers Derived from Cell Line Models.
    Voutsadakis IA
    Cancer Genomics Proteomics; 2023; 20(6):539-555. PubMed ID: 37889067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway.
    Colavito SA; Zou MR; Yan Q; Nguyen DX; Stern DF
    Breast Cancer Res; 2014 Sep; 16(5):444. PubMed ID: 25252859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterisation of cell line models for triple-negative breast cancers.
    Grigoriadis A; Mackay A; Noel E; Wu PJ; Natrajan R; Frankum J; Reis-Filho JS; Tutt A
    BMC Genomics; 2012 Nov; 13():619. PubMed ID: 23151021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
    Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
    Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.
    Sabatier R; Finetti P; Guille A; Adelaide J; Chaffanet M; Viens P; Birnbaum D; Bertucci F
    Mol Cancer; 2014 Oct; 13():228. PubMed ID: 25277734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMT Features in Claudin-Low versus Claudin-Non-Suppressed Breast Cancers and the Role of Epigenetic Modifications.
    Voutsadakis IA
    Curr Issues Mol Biol; 2023 Jul; 45(7):6040-6054. PubMed ID: 37504297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters.
    Madaras L; Balint N; Gyorffy B; Tokes AM; Barshack I; Yosepovich A; Friedman E; Paluch-Shimon S; Zippel D; Baghy K; Timar J; Kovalszky I; Kulka J; Szasz AM
    Pathobiology; 2016; 83(1):1-12. PubMed ID: 26566278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Claudin 1 expression in basal-like breast cancer is related to patient age.
    Blanchard AA; Ma X; Dueck KJ; Penner C; Cooper SC; Mulhall D; Murphy LC; Leygue E; Myal Y
    BMC Cancer; 2013 May; 13():268. PubMed ID: 23721519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
    Alsuliman A; Colak D; Al-Harazi O; Fitwi H; Tulbah A; Al-Tweigeri T; Al-Alwan M; Ghebeh H
    Mol Cancer; 2015 Aug; 14():149. PubMed ID: 26245467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-30a increases tight junction protein expression to suppress the epithelial-mesenchymal transition and metastasis by targeting Slug in breast cancer.
    Chang CW; Yu JC; Hsieh YH; Yao CC; Chao JI; Chen PM; Hsieh HY; Hsiung CN; Chu HW; Shen CY; Cheng CW
    Oncotarget; 2016 Mar; 7(13):16462-78. PubMed ID: 26918943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential.
    Knezevic J; Pfefferle AD; Petrovic I; Greene SB; Perou CM; Rosen JM
    Oncogene; 2015 Dec; 34(49):5997-6006. PubMed ID: 25746005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype.
    Lu S; Singh K; Mangray S; Tavares R; Noble L; Resnick MB; Yakirevich E
    Mod Pathol; 2013 Apr; 26(4):485-95. PubMed ID: 23222490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models.
    Dunlap SM; Chiao LJ; Nogueira L; Usary J; Perou CM; Varticovski L; Hursting SD
    Cancer Prev Res (Phila); 2012 Jul; 5(7):930-42. PubMed ID: 22588949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High
    Onaga C; Tamori S; Motomura H; Ozaki A; Matsuda C; Matsuoka I; Fujita T; Nozaki Y; Hara Y; Kawano Y; Harada Y; Sato T; Mano Y; Sato K; Akimoto K
    Anticancer Res; 2021 Jan; 41(1):43-54. PubMed ID: 33419798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers.
    Fougner C; Bergholtz H; Kuiper R; Norum JH; Sørlie T
    Breast Cancer Res; 2019 Jul; 21(1):85. PubMed ID: 31366361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
    Wahdan-Alaswad R; Harrell JC; Fan Z; Edgerton SM; Liu B; Thor AD
    Cell Cycle; 2016; 15(8):1046-59. PubMed ID: 26919310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Claudins as prognostic factors of breast cancer].
    Szász MA
    Magy Onkol; 2012 Sep; 56(3):209-12. PubMed ID: 23139925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
    Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
    Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution.
    Pommier RM; Sanlaville A; Tonon L; Kielbassa J; Thomas E; Ferrari A; Sertier AS; Hollande F; Martinez P; Tissier A; Morel AP; Ouzounova M; Puisieux A
    Nat Commun; 2020 Jul; 11(1):3431. PubMed ID: 32647202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.